All In Biotech

Drug Trial Radar · NCT00360529

24-week Placebo-controlled Trial of Flibanserin Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder

A Twenty Four Week, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trial of Flibanserin 50mg Every Evening and Flibanserin 100mg Every Evening in Women With Hypoactive Sexual Desire Disorder in North America

Last checked: Nov 20, 2026Latest source record: Jun 27, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 880 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

880

Actual

Start

Jul 2006

Primary completion

Apr 2008

Study completion Apr 2008

Sponsor

Lead sponsor
Sprout Pharmaceuticals, IncIndustry
Sponsor type
Industry
First posted
Aug 4, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is designed to assess the safety and efficacy of flibanserin in the treatment of premenopausal women with Hypoactive Sexual Desire Disorder (HSDD) that meets standard diagnostic criteria. Efficacy for flibanserin will be assessed vs. a parallel placebo group.

Conditions

  • Sexual Dysfunctions, Psychological

Interventions

  • flibanserinDrug

    flibanserin placebo versus 50 mg qhs versus 100 mg qhs

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Satisfying Sexual Event Monthly Change From Baseline at Final VisitTime frame: Baseline, Week 24
  2. Sexual Desire Monthly Change on Electronic Diary From Baseline at Final VisitTime frame: Baseline, Week 24

Locations

54 sites in 2 countries. Site status is shown where the registry gives one.

  • 511.71.01034 Boehringer Ingelheim Investigational Site

    Mobile, Alabama

  • 511.71.01042 Boehringer Ingelheim Investigational Site

    South Birmingham, Alabama

  • 511.71.01016 Boehringer Ingelheim Investigational Site

    Phoenix, Arizona

  • 511.71.01041 Boehringer Ingelheim Investigational Site

    La Mesa, California

  • 511.71.01011 Boehringer Ingelheim Investigational Site

    San Diego, California

  • 511.71.01027 Boehringer Ingelheim Investigational Site

    Westlake Village, California

  • 511.71.01035 Boehringer Ingelheim Investigational Site

    Denver, Colorado

  • 511.71.01010 Boehringer Ingelheim Investigational Site

    Groton, Connecticut

  • 511.71.01021 Boehringer Ingelheim Investigational Site

    New Britain, Connecticut

  • 511.71.01037 Boehringer Ingelheim Investigational Site

    Newark, Delaware

  • 511.71.01001 Boehringer Ingelheim Investigational Site

    Boynton Beach, Florida

  • 511.71.01032 Boehringer Ingelheim Investigational Site

    Clearwater, Florida

  • 511.71.01014 Boehringer Ingelheim Investigational Site

    Miami, Florida

  • 511.71.01025 Boehringer Ingelheim Investigational Site

    Pembroke Pines, Florida

  • 511.71.01006 Boehringer Ingelheim Investigational Site

    Plantation, Florida

  • 511.71.01015 Boehringer Ingelheim Investigational Site

    Atlanta, Georgia

  • 511.71.01038 Boehringer Ingelheim Investigational Site

    Marietta, Georgia

  • 511.71.01036 Boehringer Ingelheim Investigational Site

    Chicago, Illinois

  • 511.71.01029 Boehringer Ingelheim Investigational Site

    Evansville, Indiana

  • 511.71.01028 Boehringer Ingelheim Investigational Site

    Renton, Indiana

  • 511.71.01024 Boehringer Ingelheim Investigational Site

    New Orlean, Louisiana

  • 511.71.01040 Boehringer Ingelheim Investigational Site

    Towson, Maryland

  • 511.71.01045 Boehringer Ingelheim Investigational Site

    Brighton, Massachusetts

  • 511.71.01005 Boehringer Ingelheim Investigational Site

    St Louis, Missouri

  • 511.71.01030 Boehringer Ingelheim Investigational Site

    Albuquerque, New Mexico

  • 511.71.01007 Boehringer Ingelheim Investigational Site

    Rochester, New York

  • 511.71.01012 Boehringer Ingelheim Investigational Site

    The Bronx, New York

  • 511.71.01023 Boehringer Ingelheim Investigational Site

    New Bern, North Carolina

  • 511.71.01002 Boehringer Ingelheim Investigational Site

    Cincinnati, Ohio

  • 511.71.01044 Boehringer Ingelheim Investigational Site

    Cincinnati, Ohio

  • 511.71.01026 Boehringer Ingelheim Investigational Site

    Columbus, Ohio

  • 511.71.01039 Boehringer Ingelheim Investigational Site

    Edmond, Oklahoma

  • 511.71.01003 Boehringer Ingelheim Investigational Site

    Danville, Pennsylvania

  • 511.71.01033 Boehringer Ingelheim Investigational Site

    Philadelphia, Pennsylvania

  • 511.71.01031 Boehringer Ingelheim Investigational Site

    Pittsburgh, Pennsylvania

  • 511.71.01022 Boehringer Ingelheim Investigational Site

    Mt. Pleasant, South Carolina

  • 511.71.01020 Boehringer Ingelheim Investigational Site

    Germantown, Tennessee

  • 511.71.01017 Boehringer Ingelheim Investigational Site

    San Antonio, Texas

  • 511.71.01018 Boehringer Ingelheim Investigational Site

    San Antonio, Texas

  • 511.71.01008 Boehringer Ingelheim Investigational Site

    Huntington, West Virginia

Showing 40 of 54 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.